Used in the treatment of multicentric Castleman disease, this antibody targets interleukin-6 (IL-6), a cytokine involved in inflammation and immune response. By neutralizing IL-6, it helps reduce systemic inflammation, control disease symptoms, and improve patient outcomes. It is also investigated for use in other IL-6-driven conditions such as certain autoimmune diseases, cancers, and chronic inflammatory disorders. Its application extends to research settings for understanding IL-6 signaling pathways and evaluating therapeutic strategies in immune-mediated diseases.